Publications:437
Video Visit Available
Accepting New Patients
- Mount Sinai Doctors
- Treats Adults
- Video Visit Available
- Accepting New Patients
Sundar Jagannath, MBBS
Internal Medicine, Cancer (Oncology)
About Me
Sundar Jagannath, MBBS, is Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai and The Tisch Cancer Institute. He is a renowned expert in the research and treatment of multiple myeloma. Dr. Jagannath serves as Network Director for the Center of Excellence for Multiple Myeloma, expanding clinical research across the Mount Sinai Health System and collaborations with other institutions.
Dr. Jagannath led the multiple myeloma program from 2010 until September 2024, growing it into a leading clinical and clinical research service. Prior to joining Mount Sinai, Dr. Jagannath was chief of the multiple myeloma and transplant program at St. Vincent’s Hospital Comprehensive Cancer Center from 1998 until the hospital closed in April 2010.
Throughout his career, Dr. Jagannath has focused on developing clinical trials using novel therapeutics. Under his leadership, participation in pivotal clinical trials s has led to FDA approval of many agents, including Velcade, Lenalidomide, Pomalidomide, Carfilzomib, Daratumumab, Elotuzumab, Selinexor, Cilta-Cel, Ide-Cel and Talquetamab. A survivorship clinic, initiated by Dr. Jagannath, follows long-term patients cured of their myeloma. The goal is to unlock the secret of the success of these patients by studying their bone marrow microenvironment and immune reconstitution.
Dr. Jagannath has published more than 400 peer-reviewed articles in top journals, including the New England Journal of Medicine, Blood, the Journal of Clinical Oncology and Cancer, and authored 28 book chapters. He has received numerous recognitions and awards, including the Innovator Award and Accelerator Award from the Multiple Myeloma Research Consortium and the Waldenström Lifetime Achievement Award from the International Myeloma Society.
Language
English
Position
PROFESSOR | Medicine, Hematology and Medical Oncology
Hospital Affiliations
- Mount Sinai Morningside
- Mount Sinai Beth Israel
- Mount Sinai Brooklyn
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai West
Clinical Focus
- Multiple Myeloma
- Smoldering Myeloma
Education
MD, University of Baroda
Residency, Internal Medicine
Bronx-Lebanon Hospital Center
Residency, Internal Medicine
BronxCare Hospital Center
Residency, Internal Medicine
Wayne State University
Residency, Medical Oncology
University of Texas MD Anderson Cancer Center
Certifications
American Board of Internal Medicine
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information. Patients with Anthem Blue Cross Blue Shield (formerly known as Empire) or Molina insurance: please visit the linked pages in this message before booking to find out if out-of-network costs may apply to your next visit.
- 1199 SEIU
- AETNA - Commercial
- AETNA - Medicare
- Affinity Medicaid-Medicare-Essential Exchange
- Amidacare Medicaid
- CIGNA Healthcare
- Centivo
- Elderplan
- EmblemHealth - GHI-PPO
- EmblemHealth - HIP
- EmblemHealth - HIP-Medicaid
- EmblemHealth - HIP-Medicare
- Empire Blue Cross Blue Shield - Commercial/Exchange
- Empire Blue Cross Blue Shield - HealthPlus Medicaid
- Empire Blue Cross Blue Shield - Medicare
- Fidelis Health Care
- HealthFirst Medicaid
- HealthFirst Medicare
- Horizon NJ
- Magnacare-Health Care
- Medicare - NJ
- Medicare - NY
- Metroplus
- Multiplan PHCS
- NJ Medicaid
- NY Medicaid
- Oscar
- Oxford - Freedom and Liberty
- Partners Health Plan
- Senior Whole Health
- United Health Care - Commercial
- United Health Care - Empire Plan
- United Health Care - Oxford Care
- United Health Care - Top Tier
- VNSNY Choice Medicare
- VNSNY Select Health Medicaid
- VillageCareMax
- WellCare Health Plan
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Selected Publications
- Indirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple Myeloma. Hans C. Lee, Naresh Bumma, Joshua Richter, Jeffrey A. Zonder, James E. Hoffman, Zheng Yi Zhou, Viviana García-Horton, Mirko Fillbrunn, Hongjue Wang, Matthew Mattera, Wenxin Ma, Timothy J. Inocencio, Yingxin Xu, Evelien Bergrath, James Harnett, Tito Roccia, Kate Knorr, Glenn S. Kroog, Karen Rodriguez Lorenc, Qiufei Ma, Sundar Jagannath. Clinical Lymphoma, Myeloma and Leukemia
- Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy. Zachary M. Avigan, Jerrel Catlett, Saoirse Bodnar, Darren Pan, Adolfo Aleman, Tianxiang Sheng, Erin Moshier, Adriana C. Rossi, Shambavi Richard, Gurbakhash Kaur, Joshua Richter, Larysa J. Sanchez, Cesar Rodriguez, Hearn Jay Cho, Shafinaz Hussein, Christian Salib, Lewis R. Silverman, Sundar Jagannath, Samir Parekh, Santiago Thibaud. Clinical Cancer Research
- Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review. Shaji Kumar, Xavier Leleu, Katja C. Weisel, Rakesh Popat, Beatrice Suero, Samantha Craigie, Paul Spin, Leena Patel, Abril Oliva Ramirez, Christian Hampp, Wenzhen Ge, Qiufei Ma, Sundar Jagannath. Clinical Lymphoma, Myeloma and Leukemia
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Jagannath during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Genentech, Inc.
- GSK plc.
- Caribou Biosciences, Inc.
- Takeda Pharmaceuticals Of North America, Inc.
- Bristol-Meyers Company
- Regeneron Pharmaceuticals, Inc.
- Sanofi US Services Inc.
- Janssen Services LLC
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.